CAPR
Capricor Therapeutics, Inc.
$8.37
+0.07
(+0.84%)
Mkt Cap
481.36M
Volume
2,070,244
52W Range
2.96-40.37
Sector
Healthcare
Beta
0.53
EPS (TTM)
-2.45 USD
P/E Ratio
-12.77
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 22.27M | 25.18M | 2.55M | 244,898 | 310,250 | 1.01M | 1.67M | 2.67M | 3.19M | 3.78M | 4.17M |
| Net Income | (105.04M) | (40.47M) | (22.29M) | (29.02M) | (20.02M) | (13.66M) | (7.64M) | (15.19M) | 2.43M | (18.81M) | (12.86M) | (6.22M) |
| EPS | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 | -2.06 | -5.17 | 1.00 | -10.14 | -8.09 | -5.31 |
| Free Cash Flow | (72.72M) | (41.53M) | (27.64M) | 1.56M | (18.01M) | (10.60M) | (6.82M) | (14.18M) | (14.26M) | (16.00M) | (10.97M) | 772,131 |
| FCF / Share | -1.56 | -1.18 | -1.03 | 0.06 | -0.78 | -0.68 | -1.84 | -4.83 | -6.15 | -8.62 | -6.90 | 0.66 |
| Operating CF | (69.81M) | (40.00M) | (25.60M) | 4.92M | (16.81M) | (10.05M) | (6.82M) | (13.86M) | (14.23M) | (15.80M) | (10.82M) | 958,562 |
| Total Assets | 355.95M | 170.48M | 58.73M | 50.09M | 41.33M | 34.62M | 11.11M | 9.25M | 16.27M | 18.75M | 16.07M | 13.63M |
| Total Debt | 17.94M | 4.83M | 5.61M | 5.94M | 6.25M | 3.69M | 3.38M | 3.38M | 3.38M | 17.01M | 9.16M | 9.16M |
| Cash & Equiv | 287.85M | 11.29M | 14.69M | 9.60M | 34.89M | 32.67M | 3.90M | 4.26M | 6.14M | 3.20M | 5.57M | 8.03M |
| Book Value | 305.79M | 145.46M | 22.60M | 11.79M | 31.37M | 28.20M | 6.84M | 4.62M | 11.23M | (4.00M) | (1.03M) | (6.25M) |
| Return on Equity | -0.34 | -0.28 | -0.99 | -2.46 | -0.64 | -0.48 | -1.12 | -3.29 | 0.22 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 11.13M | 2.26M | 3.97M | 4.91M | 12.09M | 6.19M |
| Net Income | (40.73M) | (33.94M) | (30.17M) | (24.57M) | (25.91M) | (24.39M) | (7.12M) | (12.56M) | (11.00M) | (9.79M) | (762,089) | (6.39M) |
| EPS | -0.70 | -0.59 | -0.62 | -0.54 | -0.57 | -0.53 | -0.16 | -0.38 | -0.35 | -0.31 | -0.02 | -0.25 |
| Free Cash Flow | (37.39M) | (40.00M) | (28.69M) | (23.70M) | (21.57M) | (7.57M) | (15.53M) | (11.70M) | (12.37M) | (1.93M) | (12.32M) | (9.43M) |
| FCF / Share | -0.65 | -0.70 | -0.59 | -0.52 | -0.47 | -0.17 | -0.44 | -0.35 | -0.39 | -0.06 | -0.46 | -0.37 |
| Operating CF | (31.49M) | (29.25M) | (23.57M) | (19.69M) | (20.12M) | (6.43M) | (14.80M) | (11.64M) | (12.29M) | (1.27M) | (11.59M) | (8.79M) |
| Total Assets | 368.74M | 326.28M | 355.95M | 126.44M | 133.57M | 153.77M | 170.48M | 92.95M | 38.28M | 49.44M | 58.73M | 37.15M |
| Total Debt | 91.05M | 21.12M | 17.94M | 17.92M | 4.42M | 4.63M | 4.83M | 5.02M | 5.21M | 5.40M | 5.61M | 5.79M |
| Cash & Equiv | 20.94M | 105.42M | 287.85M | 19.51M | 23.24M | 28.79M | 11.29M | 68.38M | 10.69M | 6.21M | 14.69M | 8.98M |
| Book Value | 246.22M | 278.70M | 305.79M | 83.87M | 104.98M | 127.65M | 145.46M | 68.26M | 11.50M | 18.43M | 22.60M | (1.79M) |
| Return on Equity | -0.17 | -0.12 | -0.10 | -0.29 | -0.25 | -0.19 | -0.05 | -0.18 | -0.96 | -0.53 | -0.03 | N/A |
CAPR News
Robbins LLP Reminds Capricor Therapeutics, Inc. Stockholders of the Securities Fraud Class Action After the Company's Stock Fell 64%
Kaplan Fox Encourages Capricor Therapeutics, Inc. (CAPR) Investors Who Suffered Losses to Seek a Leadership Role Before September 28, 2026
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
DEADLINE ALERT for BE, CAPR, RXT, GPGI: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline
Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to an Approaching Lead Plaintiff Deadline on September 28, 2026
CAPR Class Alert: Capricor Therapeutics Securities Fraud Class Action to Recover Losses is Pending – Investors Notified to Contact BFA Law before September 28 Court Deadline
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
CAPRICOR DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CAPR